Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2019-05-06 Director's Dealing
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing
2019-05-06 English
Director's Dealing 2019
Director's Dealing
2019-05-06 English
AMENDMENT NO. 2
Major Shareholding Notification
2019-05-06 English
Director's Dealing 2019
Director's Dealing
2019-05-02 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2019, reporting the entry into a material definitive agreement related to a securities purchase agreement and private placement of common stock and warrants. It details the terms of the offering, the parties involved, fees paid to the placement agent, and includes exhibits such as the purchase agreement and warrant forms. The content focuses on financing activities, specifically the issuance of shares and warrants, and the related capital raising transaction. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory filing for certification or voting results, nor is it a management or earnings discussion. The primary subject is the company's capital raising transaction and related agreements, which fits the Capital/Financing Update category.
2019-05-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a securities offering, specifically a common stock offering with warrants. It includes detailed information about the offering terms, pricing, placement agent fees, risk factors, use of proceeds, and legal matters. The document references SEC registration statements and compliance with securities laws. This type of document is used to inform investors about a capital raising event and the terms of the securities being offered. It is not a financial report, earnings release, management discussion, or any other type of report. It is clearly a capital/financing update related to a stock offering and private placement of warrants. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2019-05-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.